CEPTUR THERAPEUTICS

ceptur-therapeutics-logo

Ceptur is developing unique and differentiated genetic medicines for patients with unaddressed diseases. The Company’s wholly owned and proprietary U1 Adaptor technology promotes non-genotoxic and long-lasting silencing of disease-causing genes in difficult to target tissues (i.e., outside of the liver and CNS).

#People #Financial #Website #More

CEPTUR THERAPEUTICS

Social Links:

Industry:
Biotechnology Medical Therapeutics

Founded:
2008-01-01

Address:
Hillsborough, New Jersey, United States

Country:
United States

Website Url:
http://www.Cepturtx.com

Total Employee:
11+

Status:
Active

Email Addresses:
[email protected]

Total Funding:
81.2 M USD

Technology used in webpage:
SPF Microsoft Exchange Online Amazon Office 365 Mail Microsoft Azure DNS GoDaddy DNS AWS Global Accelerator WPForms



Current Advisors List

aaron-royston_image

Aaron Royston Board Member @ Ceptur Therapeutics
Board_member
2022-01-01

colin-walsh_image

Colin Walsh Board Member @ Ceptur Therapeutics
Board_member
2022-01-01

Current Employees Featured

keith-harrison-dewedoff_image

Keith-Harrison Dewedoff
Keith-Harrison Dewedoff Interim CFO @ Ceptur Therapeutics
Interim CFO
2021-05-01

paiman-peter-ghoroghchian_image

Paiman Peter Ghoroghchian
Paiman Peter Ghoroghchian Co-Founder, President, and CEO @ Ceptur Therapeutics
Co-Founder, President, and CEO
2020-08-01

not_available_image

Rafal Goraczniak
Rafal Goraczniak Co-founder and Director of Platform Development @ Ceptur Therapeutics
Co-founder and Director of Platform Development

christoph-rosenbohm_image

Christoph Rosenbohm
Christoph Rosenbohm CTO @ Ceptur Therapeutics
CTO
2021-11-01

Founder


paiman-peter-ghoroghchian_image

Paiman Peter Ghoroghchian

not_available_image

Rafal Goraczniak

not_available_image

Samuel Gunderson

Investors List

bristol-myers-squibb_image

Bristol Myers Squibb

Bristol Myers Squibb investment in Series A - Ceptur Therapeutics

qiming-venture-partners_image

Qiming Venture Partners

Qiming Venture Partners investment in Series A - Ceptur Therapeutics

affinity-asset-advisors_image

Affinity Asset Advisors

Affinity Asset Advisors investment in Series A - Ceptur Therapeutics

boxer-capital_image

Boxer Capital

Boxer Capital investment in Series A - Ceptur Therapeutics

perceptive-advisors_image

Perceptive Advisors

Perceptive Advisors investment in Series A - Ceptur Therapeutics

janus-henderson-investors_image

Janus Henderson Investors

Janus Henderson Investors investment in Series A - Ceptur Therapeutics

venbio_image

venBio Partners

venBio Partners investment in Series A - Ceptur Therapeutics

lifesci-venture-partners_image

LifeSci Venture Partners

LifeSci Venture Partners investment in Series A - Ceptur Therapeutics

affinity-asset-advisors_image

Affinity Asset Advisors

Affinity Asset Advisors investment in Venture Round - Ceptur Therapeutics

Official Site Inspections

http://www.Cepturtx.com

  • Host name: 172.67.207.39
  • IP address: 172.67.207.39
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Ceptur Therapeutics"

Ceptur Therapeutics - Crunchbase Company Profile

Contact Email [email protected] Ceptur is developing unique and differentiated genetic medicines for patients with unaddressed diseases. The Company’s wholly owned and proprietary U1 Adaptor technology promotes …See details»

Ceptur Therapeutics Company Profile 2024: Valuation, …

Ceptur Therapeutics General Information Description. Developer of U1 adaptor technology designed to facilitate the creation of treatment. The company's technology overcomes the limitations of gene silencing technologies and …See details»

Ceptur Therapeutics Company Profile | Management and

Www.cepturtx.com Ceptur Therapeutics Profile and History Headquartered in Hillsborough New Jersey, Ceptur Therapeutics is a pre-clinical stage biotechnology company focused on …See details»

Ceptur Therapeutics - Overview, News & Similar companies

Mar 14, 2022 www.cepturtx.com. Revenue <$5 Million. Industry Business Services General Business Services . Recent News & Media. Ceptur Appoints Romesh Subramanian to Its …See details»

Ceptur Therapeutics Launches with $75M Series A …

Jan 19, 2022 He is further a member of the European Molecular Biology Organization (EMBO) and helped to make The EMBO Journal a highly successful international publication, acting as Executive Editor from 1990 ...See details»

Ceptur Therapeutics - Company Profile & Staff Directory

Ceptur is developing unique and differentiated genetic medicines for patients with unaddressed diseases. The Company’s wholly owned and proprietary U1 Adaptor technology promotes non …See details»

CEPTUR THERAPEUTICS, INC. - Dun & Bradstreet

Find company research, competitor information, contact details & financial data for CEPTUR THERAPEUTICS, INC. of Hillsborough, NJ. Get the latest business insights from Dun & …See details»

Series A - Ceptur Therapeutics - 2022-01-19 - Crunchbase

Jan 19, 2022 Organization Name . Ceptur Therapeutics . Announced Date Jan 19, 2022; Closed On Date Feb 14, 2022; Funding Type Series A; Funding Stage Early Stage Venture; Money …See details»

Ceptur Therapeutics - VentureRadar

Dansk Biotek Unknown n/a DANISH BIOTECH is a trade organization for Danish biotech companies with the aim to promote opportunities for biotechnology research, development and …See details»

A new RNA-based drug startup launches with Rutgers …

Jan 19, 2022 A Philadelphia-based biotech startup has raised an early round of cash to fund the development of RNA-based drugs that leverage a novel scientific discovery to shut down disease-causing genes.See details»

Ceptur Appoints Romesh Subramanian to Its Board of …

Mar 21, 2022 Ceptur Therapeutics, Inc. (“Ceptur”), a biotechnology company focused on the development of targeted oligonucleotides for gene silencing and RNA editiSee details»

cepturtx.com

Sep 7, 2021 cepturtx.com ... TaglineSee details»

Bristol Myers, VCs launch new RNA therapeutics biotech ... - Fierce …

Jan 19, 2022 Since Ceptur's oligos don't require an enzyme as part of the drug's effect on the body, there could be potential to avoid the two-step delivery needed by gene editing …See details»

Ceptur Therapeutics Launches with $75M Series A Financing to …

Jan 20, 2022 Dr. Mattaj was previously awarded the prestigious Louis-Jeantet Prize for Medicine in 2001. He is further a member of the European Molecular Biology Organization (EMBO) and …See details»

Ceptur Therapeutics Launches with $75M Series A Financing to

Jan 19, 2022 He is further a member of the European Molecular Biology Organization (EMBO) ... Keith Dewedoff, (215)-330-8399, [email protected]. Source: Ceptur Therapeutics, Inc. …See details»

Ceptur Therapeutics Launches with $75M Series A Financing to …

Jan 19, 2022 PHILADELPHIA--(BUSINESS WIRE)-- Ceptur Therapeutics, Inc. (“Ceptur”), a biotechnology company focused on developing targeted oligonucleotide therapeutics based on …See details»

@CepturTx | X

The latest posts from @CepturTxSee details»

Ceptur Therapeutics Launches with $75M Series A Financing to …

Jan 19, 2022 Financing co-led by venBio Partners &amp; Qiming Venture Partners USA with participation from strong syndicate of new and existing investors Pioneering new wave of …See details»

Ceptur Therapeutics Launches with $75M Series A Financing to …

Jan 19, 2022 4dd8868ea336.C57VY8eNiJPDimV8aDMMUg6E32Bs_GhqHeIUggvRhHU.OvKlEoT0vf617j0ZAWxkZWXC5lUeqCcZLK1iwEGr90d8po0ZpMfO8vHcBg …See details»

Ceptur Therapeutics Launches with $75M Series A Financing to …

PHILADELPHIA–(BUSINESS WIRE)–Ceptur Therapeutics, Inc. (“Ceptur”), a biotechnology company focused on developing targeted oligonucleotide therapeutics based on U1 Adaptor …See details»

linkstock.net © 2022. All rights reserved